By Colin Kellaher

 

Roche Holding AG's (ROG.EB) Genentech unit Tuesday said a phase II study of Gazyva met its primary and key secondary endpoints in adults with the kidney disorder proliferative lupus nephritis.

Genentech said Gazyva in combination with standard of care showed enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year.

Gazyva also showed improved overall renal responses and serologic markers of disease activity compared to placebo, the company said.

Genentech said there are currently no FDA-approved therapies for lupus nephritis, a potentially life-threatening condition in which patients are at high risk for progressing to end-stage renal disease or death.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

June 11, 2019 07:10 ET (11:10 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Roche (QX) Charts.